Pfizer Inc. (NYSE:PFE) Shares Acquired by Eagle Rock Investment Company LLC

Eagle Rock Investment Company LLC boosted its position in Pfizer Inc. (NYSE:PFE) by 16.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 282,347 shares of the biopharmaceutical company’s stock after purchasing an additional 40,806 shares during the quarter. Pfizer comprises about 1.4% of Eagle Rock Investment Company LLC’s holdings, making the stock its 19th largest position. Eagle Rock Investment Company LLC’s holdings in Pfizer were worth $8,171,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Olistico Wealth LLC purchased a new stake in Pfizer in the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer during the 2nd quarter valued at approximately $29,000. Quarry LP acquired a new stake in shares of Pfizer during the 2nd quarter valued at approximately $31,000. Creekmur Asset Management LLC bought a new position in Pfizer during the 4th quarter worth $32,000. Finally, Trivant Custom Portfolio Group LLC grew its stake in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE traded up $0.86 on Monday, hitting $29.44. The company had a trading volume of 29,832,717 shares, compared to its average volume of 37,345,422. The company’s fifty day moving average price is $29.17 and its 200 day moving average price is $28.32. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $33.92. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The stock has a market cap of $166.82 billion, a price-to-earnings ratio of -490.67, a price-to-earnings-growth ratio of 1.23 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.67 EPS. Equities analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. StockNews.com cut Pfizer from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st. Wells Fargo & Company increased their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Thursday. Nine investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.